AZ links with ArcherDX to detect minimal residual disease in lung cancer patients

26th May 2020 Uncategorised 0

ArcherDX will perform whole exome sequencing of NSCLC patient samples to generate personalised ctDNA assays to test for MRD

More: AZ links with ArcherDX to detect minimal residual disease in lung cancer patients
Source: News